Chugai stock drops the most since 1977 on disappointing obesity drug data
Tomas Kauer - News Writer and Moderator 
A study showed the drug, which it has licensed to Eli Lilly & Co., resulted in lower weight loss and higher rates of nausea and vomiting than anticipated.
